Biotech giant Pfizer Inc. (NYSE: PFE) has provided BioNTech SE (NASDAQ: BNTX) data on the COVID-19 vaccine it is creating. Interim phase III results indicate that compared to placebo, the vaccine offers 90 percent efficacy. The news has been a catalyst of growth in the shares of a number of firms whose business depends directly on the early lifting of restrictions. Pfizer itself has also begun accepting vaccine orders.
Pfizer and BioNTech have so far obtained pre-orders from 13 countries and the European Union for more than 573 million doses of their BNT162b2 COVID-19 vaccine and have agreed to supply an additional 600 million doses of the vaccine. The most probable candidates for early acceptance are the growth of businesses. In addition, the vaccine may, by the end of this year, be approved for emergency use by regulators in the EU and the US.
The Pfizer and BioNTech vaccine studies include more than 43,000 volunteers from different ethnic groups and positive evidence is reported regardless of the ethnicity of the subject. This means that, in various geographical regions, the vaccine can be equally effective. Also, no safety problems have yet been identified. The company’s testing is done in an open environment, which ensures that the potency of the vaccine is not greatly compromised by viral mutations, because patients are exposed to strains of the virus currently circulating. Thus, the BNT162b2 vaccine currently shows high effectiveness, ethnic universality, and protection in all active virus strains. The pandemic will stop if further research confirms previous successes and vaccination begins.
By the end of 2021, Pfizer and BioNTech plan to manufacture 1.3 billion doses of BNT162b2. Pfizer and BioNTech have the ability to produce $26 billion in revenue from BNT162b2 with a price tag of $20 per dosage.
On Thursday, Pfizer Inc. (PFE) was down -2.47 at $37.55 and BioNTech SE (BNTX) sank 7.14 percent to $101.63, but over the week companies’ stocks rose by 3.19 percent and 10.47 percent respectively.